More biobucks this morning, out of Rahway -- to Santa Cruz. This is a peptide discovery deal, using AI, to seek therapeutic targets for "challenging" cancers. Merck continues to invest heavily, but wisely -- in its future.
As ever, this amount is immaterial to Merck, but certainly validates Unnatural Products' approach. Let's listen in to
FiercePharma, on it all this morning:
. . .Months after hailing macrocyclic peptides as the “next wave of drug discovery,” Merck & Co. has pushed further into the space by penning a $220 million biobucks deal with Unnatural Products.
The California-based biotech uses its combination of AI and chemistry expertise to “address the complexities of medicinal chemistry in the macrocycle space,” the company said in a Jan. 23 release. Now, Merck has tapped up UNP to apply its tech to develop macrocyclic candidates against a “challenging” undisclosed oncology target. . . .
Now you know -- with the end of the snow. . . transitioning to a soft, warmer rain, now. Grinning. . . .
नमस्ते
No comments:
Post a Comment